John Mendelsohn - Merrimack Pharmaceuticals Insider

Merrimack Pharmaceuticals Inc -- USA Stock  

USD 9.70  0.01  0.10%


Dr. John Mendelsohn, M.D. is an Independent Director of the Company. He has served as a member of our board of directors since June 2012. Dr. Mendelsohn has served as the CoDirector of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center since September 2011. Dr. Mendelsohn also served as President of the MD Anderson Cancer Center from 1996 to August 2011. Prior to joining the MD Anderson Cancer Center, Dr. Mendelsohn was founding director of the cancer center at the University of California San Diego and served as Chairman of Medicine at Memorial SloanKettering Cancer Center from 1985 to 1996. Dr. Mendelsohn also currently serves as the L.E. and Virginia Simmons Senior Fellow in Health and Technology Policy at the James A. Baker, III Institute for Public Policy. Dr. Mendelsohn is recognized for his research on the binding of growth factors to cell surface receptors and how they regulate cell functions, which led to the discovery, development and eventual commercialization of the cancer therapy cetuximab
Age: 78  Director Since 2012      
Mendelsohn holds an M.D. from Harvard Medical School and a B.S. from Harvard College.

John Mendelsohn Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (29.74) % which means that it has lost $29.74 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (19.0) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 49.88 M in liabilities with Debt to Equity (D/E) ratio of 44.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Merrimack Pharmaceuticals Inc has Current Ratio of 3.28 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange.Merrimack Pharmaceuticals Inc (MACK) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 294 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Equity Analysis Now

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Hide  View All  NextLaunch Equity Analysis

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Merrimack Pharmaceuticals Inc to your portfolio

Top Management

Merrimack Pharmaceuticals Leadership Team
Robert Mulroy, CEO
George Demetri, Director
Gary Crocker, Chairman, MBA
Vivian Lee, Director, MBA
James Quigley, Director, Ph.D
Birgit Schoeberl, Executive
Richard Peters, CEO, Ph.D
Ulrik Nielsen, SVP
John Mendelsohn, Director
John Green, Executive
Ellen Forest, Executive
Yasir AlWakeel, CFO, Ph.D
Edward Stewart, President, MBA
Jean Franchi, CFO, CPA
William Sullivan, Executive, MBA
William Mcclements, Executive, MBA
John Dineen, Director
Russell Ray, Director, MBA
Peter Laivins, Executive, MBA
Michael Porter, Director, MBA
Geoffrey Grande, Executive
Sergio Santillana, Executive

Stock Performance

Merrimack Pharmaceuticals Performance Indicators